Charles River Laboratories International, Inc.
NYSE:CRLMedical - Diagnostics & Research
-$2.45 today
- Market cap
- $15.97B
- Beta
- 1.45
- P/E (TTM)
- -48.3
- EPS (TTM)
- -$3.77
Volume 0.52M
Average 0.86M
CRL EBITDA Margin
EBITDA as a percentage of revenue.
Charles River Laboratories International, Inc.NYSE: CRL
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin narrows to 15.0%
EBITDA Margin was 15.0% in Q2 FY2026, down 6.4 pp from a year earlier. On a trailing-twelve-month basis it was 5.5%, down 7.6 pp year over year. Over 3 fiscal years it narrowed by 14.6 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 10 analysts of 33.0% for the fiscal year ending Dec 2026, up from 10.2% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 15.0%+8.6 pp QoQ
- Last fiscal yearDec 2025
- 10.2%-4.1 pp YoY
- LTMJun 2026
- 5.5%-7.6 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -6.4 pp | +12.2 pp | +18.6 pp |
| 1 year | -4.1 pp | +22.7 pp | +26.9 pp |
| 3 years | -14.6 pp | +24.0 pp | +38.6 pp |
| 5 years | +24.1 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 10.2%
- Year-over-year change
- -4.1pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-27 | 10.2% | -4.1pp |
| FY2024 | 2024-12-28 | 14.3% | -10.6pp |
| FY2023 | 2023-12-31 | 25.0% | +0.2pp |
| FY2022 | 2022-12-31 | 24.8% | +1.6pp |
| FY2021 | 2021-12-31 | 23.2% | — |
EBITDA Margin vs competitors
How CRL compares with its peers on the latest reported figures
- CRL's LTM Jun 2026 EBITDA Margin of 5.5% is the lowest of the 4 companies compared; the peer median is 22.7%.
- Its year-over-year change of -7.6 pp is the lowest of 4, against a peer median of -0.6 pp.
- Over three fiscal years its change of -14.6 pp compares with a peer median of -6.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 24.1% | +9.7 pp | -6.5 pp | |
| LTM Sep 2026 | 22.7% | -0.6 pp | +1.4 pp | |
| LTM Jun 2026 | 15.1% | -1.9 pp | -7.7 pp | |
| LTM Jun 2026 | 5.5% | -7.6 pp | -14.6 pp | |
| Peer median (excluding CRL) | 22.7% | -0.6 pp | -6.5 pp | |
Competitors are the stored peer set for CRL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.54B | 3.98B | 4.13B | 4.05B | 4.02B |
| Cost of Revenue | 2.21B | 2.51B | 2.63B | 2.72B | 2.79B |
| Gross Profit | 1.33B | 1.46B | 1.5B | 1.33B | 1.23B |
| Gross Margin | 37.7% | 36.8% | 36.4% | 32.9% | 30.5% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 619.92M | 665.1M | 747.86M | 751M | 743.07M |
| Operating Expenses | 744.78M | 811.68M | 885.3M | 1.1B | 717.73M |
| Depreciation & Amortization | 265.54M | 303.87M | 314.12M | 361.74M | 403.31M |
| EBITDA | 820.16M | 986.15M | 1.03B | 581.14M | 410.84M |
| EBITDA Margin | 23.2% | 24.8% | 25.0% | 14.3% | 10.2% |
| Operating Income | 589.86M | 650.98M | 617.26M | 227.35M | 507.84M |
| Operating Margin | 16.7% | 16.4% | 14.9% | 5.6% | 12.6% |
| Interest Income | 652K | 780K | 5.2M | 8.58M | 4.94M |
| Interest Expense | 73.91M | 59.29M | 136.71M | 126.29M | 107.03M |
| Other Income / Expenses | (109.15M) | (27.99M) | (35.98M) | (134.23M) | (607.34M) |
| Income Before Tax | 480.71M | 622.99M | 581.28M | 93.11M | (99.5M) |
| Pre-Tax Margin | 13.6% | 15.7% | 14.1% | 2.3% | -2.5% |
| Income Tax Expense | 81.87M | 130.38M | 100.91M | 67.82M | 42.66M |
| Net Income | 390.98M | 486.23M | 474.62M | 10.3M | (144.34M) |
| Net Margin | 11.0% | 12.2% | 11.5% | 0.3% | -3.6% |
| EPS (Basic) | 7.77 | 9.57 | 9.27 | 0.20 | (2.91) |
| EPS (Diluted) | 7.60 | 9.48 | 9.22 | 0.20 | (2.91) |
| Weighted Avg Shares | 50.29M | 50.81M | 51.23M | 51.38M | 49.56M |
| Weighted Avg Shares (Diluted) | 51.43M | 51.3M | 51.45M | 51.63M | 49.56M |
Charles River Laboratories International, Inc.
NYSE:CRL
Intrinsic Alpha fair value
Locked
Current Price
$333.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.